ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today presented results from a pilot study examining INNO-305, a Wilms Tumor Protein (WT1) heteroclitic peptide immunotherapeutic vaccine, in patients with myeloid and thoracic neoplasms. Preliminary data from the pilot study suggests repeat administration with INNO-305 is well tolerated and immune response can be elicited following three vaccinations. The data were presented at the 49th American Society of Hematology (ASH) Annual Meeting in Atlanta.
